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Inspector Gregory – ‘‘Is there any other point to which you wish to draw my attention, Mr Holmes?’’
Sherlock Holmes – ‘‘To the curious incident of the dog in the night time.’’
Inspector Gregory – ‘‘But the dog did nothing in the night time!’’
Sherlock Holmes – ‘‘That was the curious incident!’’
from Silver Blaze by Sir Arthur Conan Doyle
Photochemotherapy with 8-methoxypsoralen and long
wavelength ultraviolet radiation (PUVA) is commonly
used to treat psoriasis and vitiligo. These vastly different
diseases respond to the therapy by different mechanisms
even though the immediate effects of the therapy –
photoadduct formation – is the same for both. Because
psoriasis is not cured by PUVA, patients receive many
treatments over their lifetime and develop a significant
risk for the development of skin cancers (primarily
squamous cell carcinomas). In this review the basic
aspects of psoralen photobiology are reviewed briefly. In
addition the impact of the analysis of mutations in
the tumor suppressor gene, p53, are summarized. An
The widespread interest in tumor suppressor proteins, andp53 in particular, stems from their central role incarcinogenesis. The p53 gene was initially thought tobe an oncogene because p53 was detected at elevatedlevels in transformed cells and overexpression seemed to
result in transformation of normal cells (Linzer and Levine, 1979;
Eliyahu et al, 1984). p53, however, was later found to function as a
tumor suppressor when additional studies revealed that transformed
cells contained mutated p53, and that transfection of transformed cells
with wild-type p53 resulted in cell death. As additional studies have
elucidated its cellular activity various labels have been applied to the
protein. The label ‘‘the guardian of the genome’’ (Lane, 1992) was
indicative of its effects in DNA repair. The term ‘‘gatekeeper’’ came
in to vogue more recently as the role of p53 in apoptosis and cell
cycle regulation became evident (Levine, 1997). For a list of reviews
of diverse functions p53 see Table I.
p53 functions to integrate cellular responses to stress. Depending on
the nature of the stress, p53 will either cause cell cycle arrest, induce
apoptosis, or activate cell differentiation. p53 is associated with the
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unexpected mutation spectrum (very few T→A trans-
versions and frequent UVB signature C→T transitions)
suggest that effects other than direct DNA photoadduct
formation may be at play. The roles of reactive oxygen
species-induced base changes as well as other clastogenic
factors are discussed. This analysis suggests that it may
be possible to improve the therapeutic efficacy of PUVA
by a careful evaluation of the mode of delivery. Key words:
5-methylcytosine/8-hydroxyguanine/melanoma/mutation/p53/
photoadduct/psoriasis/PUVA/squamous cell carcinoma. Journal
of Investigative Dermatology Symposium Proceedings 4:11–
16, 1999
repair of DNA damage and arrests cells at the transition from G1 to S
phase. p53 also regulates the transition from G2 to M phase. One
mechanism by which p53 regulates cell cycle arrest and apoptosis is
through transcriptional activation of genes that promote apoptosis or
growth arrest. Mutations in the DNA binding region (exons 5–8) of
p53 have been found in approximately 50% of all human cancers.
Mutations in this region alter p53 function as a transcription factor.
Both p53 alleles are lost in most human tumors. Loss of heterozygosity
(LOH) is commonly observed in one allele while the second contains
a missense mutation that inactivates the gene. One model for skin
cancer predicts that loss of p53 may result in a gain of function.
Genotoxic damage from agents such as UV irradiation should result
in death in cells containing wild-type p53; however, as long as the
damage is not lethal, p53 null cells may survive and undergo clonal
expansion. It appears that deleterious p53 mutations, usually found in
the DNA binding region of the protein (exons 5–8), reduce its capacity
to bind to damaged sites and hence replication occurs with reduced
fidelity leading to cell transformations and cancer. More recently a
proteolytic function for p53 has been described (see Table I).
In its role as a transcription factor it has also been suggested that
mutated forms of p53 may interact with different sets of transcription
sites, leading to the increased proliferation of cells characteristic of
neoplasms (Dittmer et al, 1993). In addition to being the most common
genetic defect in human cancers, in the instances of cancers arising
from definitive causative agents, the p53 mutational spectrum may
display a characteristic fingerprint that can be correlated with the DNA
damage specificity of that agent [such as UVB radiation (Brash et al,
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Table I. Recent p53 review articles and their focus
Cancer etiology, molecular pathogenesis (Greenblatt et al, 1994)
Broad review describing multiple functions of p53 (Ko and Prives, 1996)
Growth control and neoplasia (Gottlieb and Oren, 1996)
p53, the cellular gatekeeper for growth and division (Levine, 1997)
p53 proteolysis (Okorokov et al, 1997)
p53, the cellular gatekeeper for growth and division (Levine, 1997)
tp53 ubiquitination (Scheffner, 1998)
1991), aflatoxin (Hollstein et al, 1993), and oxidative processes (Kreutzer
and Essigmann, 1998)]. In a different kind of role, p53 expression and
mutation have been found to occur in nontumorigenic indications
such as rheumatoid arthritis and keloid formation (for a review see
Gasparro, 1998).
The correlation between squamous cell carcinoma (SCC) incidence
and mutations in p53 tumor suppressor gene has been well characterized.
Signature mutations at pyrimidines and dipyrimidine sites observed by
several independent investigators have been attributed to the UV-
induced formation of pyrimidine dimers (Brash et al, 1991 and references
therein). Whereas the presence of a given mutation cannot be taken
as any kind of proof of cause, the distribution of mutations from a
group of specimens produces a mutation spectrum that can be indicative
of important molecular events in that population. The tracing of
possible causative events in this manner has led to the development of
the field called molecular epidemiology. Although it may seem there
could be no more objective analysis than this, it must be kept in mind
that molecular events occuring earlier in the carcinogenesis process
may not be evident in the tissue that is ultimately analyzed, namely
cancerous tissue. Further complicating matters is the complex nature
of a tumor specimen that usually contains a mixture of normal and
neoplastic cells. Ren et al (1997) have demonstrated the powerful
amplification of signal to noise using a microdissection technique that
distinguished different regions of tumors based on staining with anti-
p53 antibodies.
A commonly accepted scheme for the development of tumors after
exposure to a DNA damaging agent results in lesions that may or may
not be repaired accurately. In addition, persisting adducts may lead to
replication errors and or misincorporations. These events can result in
mutations. If the latter are critical, the cell does not survive; however,
a nonlethal mutation in a gene like p53 could provide a selective
advantage for the proliferation of mutation-containing cells. Minimally
the loss of normal p53 function would be akin to a speeding car with
no brakes.
The foregoing could be a more or less complete picture for an
internal tumor caused by an agent like aflatoxin; however, in the case
of skin cancer, another effect of mutation-inducing UV radiation must
be considered as it has also been shown to be a potent immune
suppressive agent (Vink et al, 1997). Thus, a p53 mutation that could
confer a selective growth advantage for a particular cell may also occur
on a background that includes reduced immune surveillance in the
UV-exposed skin (for a recent and thorough review see Streilein,
1996). The potential effects of immune suppression in cancer induction
are illustrated by the types of mutations observed in psoriasis patients
who have developed SCC after extensive PUVA therapy.
p53 mutations in nonmelanoma skin cancer Molecular epide-
miology offers a potent tool to elucidate contributing factors in the
cause of cancers. As stated above mutations in the tumor suppressor
protein p53 have been detected in more than 50% of all cancers.
Furthermore, causative agents lead to distinctive mutational spectra.
For example, in skin cancers from sun-exposed sites it is common to find
C→T and CC→TT transitions at DNA sequences where pyrimidine
photochemical events are expected to occur. Although it may be stated
that it was known that sunlight caused skin cancers, the mutation
spectrum in the p53 gene directly implicates DNA damage and mutated
p53. Other effects such as UV-induced immune suppression may occur
with a different action spectrum and contribute to the development
of skin cancer. The wavelength dependence for immune suppression
in human skin has not been characterized; however, the immune
Figure 1. 8-MOP UV absorption spectrum, UVA Lamp output, and
8-MOP structure. The use of UVA to activate 8-MOP may appear less
efficient than other wavelengths such as UVB (280–300 nm). The selection of
UVA was based on the uncorrected excitation spectrum of 8-MOP (A. Lerner,
personal communication). The reduced number of photons at the shorter UV
wavelengths near 300 nm caused a reduction in 8-MOP excitation efficiency,
resulting in a skewed maximum. Inset, 8-MOP structure.
suppressive effects of PUVA have been described (Kripke, 1984; Alcalay
et al, 1989).
SCC in PUVA-treated psoriasis patients In PUVA for psoriasis,
genotoxic damage is intentionally inflicted on the skin (Parrish et al,
1974). Thus, it was not too surprising to find in a study of the 1380
patients from the original U.S. multicenter PUVA trial, that a 2.6-fold
increase in the incidence of cutaneous SCC was observed as early as
5 y after therapy began (Stern et al, 1979). In the most recent report
by Stern et al (1998), the further analysis of skin cancers in this cohort
is presented. For those patients without an SCC or BCC in the first
decade, there was a strong dose-dependent increase in SCC in the
second decade. A much less impressive effect was observed for basal
cell carcinoma (BCC). High-dose patients (more than 337 PUVA
treatments) carried an 68-fold increase in the overall risk of SCC with
lower risks of 26- and 5-fold for medium- and low-dose exposures
(160–336 and , 100 treatments, respectively), whereas only a 4-fold
BCC increase was observed for all dosages. Whereas in early studies
there appeared to be differences in European and American experiences
with PUVA-induced incidence of SCC, the ongoing periodic re-
analysis of each set of data with a longer follow-up period, now
indicates comparable findings (Studniberg and Weller, 1993).
A recent report described the increased risk of malignant melanoma
in the PUVA cohort (Stern et al, 1997). Of the 1380 patients in the
PUVA cohort, seven developed malignant melanoma at a period of
15 y. Patients who received 250 or greater PUVA treatments had a
5.5-fold increase in the relative risk of malignant melanoma, whereas
those who received fewer treatments had only a 1.3-fold increase. The
significance of these early data can only be confirmed by additional
follow-up analyses; however, their occurence so many years after the
start of PUVA suggests the possibility of a different mechanism than
for SCC development in the same PUVA cohort. Clues as to the
etiology of melanomas in PUVA patients may be provided by the
analysis of p53 mutations. In a recent analysis of 11 melanocytic lesions
from 11 PUVA patients, we examined exons 5–8 and found one PUVA
type mutation (A→T transversion at codon 139; Ren et al, 1999a).
This lesion was from a patient for whom we analysed four SCC and
found seven mutations, including four separate T→G PUVA-type
transversions at codon 205 (Ren et al, 1999b). The relatively infrequent
occurence of mutations in melanomas compared with other cancers
may be the result of the limited analysis of exons (typically 5–8). But
it must not be forgotten that the role of p53 may not be as important
as in SCC and another mutated gene may contribute to the development
of melanomas.
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Psoralen photochemistry and mutagenesis Psoralens are planar,
tricyclic compounds, consisting of a furan ring fused to a coumarin
moiety exhibiting absorption bands between 200 and 350 nm (Fig 1)
(Moor and Gasparro, 1996). The planar structure and hydrophobicity
of psoralens leads to their facile intercalation with nucleic acid base
pairs. Upon photoactivation, different adducts (addition to DNA bases)
can be formed (Fig 2). Based on in vitro photochemical analyses, the
most frequently occuring photoadducts are expected to be the thymid-
ine adducts, followed by cytosine adducts (10–20 times less efficiently)
(Cimino et al, 1985) at 59TpA dinucleotide sites. Although a photoaddi-
tion product to adenine has only been detected under in vitro conditions
(Yun et al, 1992), no psoralen adduct with guanine has been reported;
however, it is important to note that guanine often serves as a sink for
oxidative damage that cannot be detected by conventional optical
methods (see below). Furthermore, the production of oxygen radical
mediated clastogenic factors (mixture of lipid peroxidation products,
cytokines, and unusual nucleotides) by PUVA in vivo could lead to
chromosomal instability that may contribute to the cancer risk in
PUVA patients (Filipe et al, 1997). Furthermore, Lewis and Adams
(1987) have shown that the induction of reactive oxygen species
without 8-hydroxyguanine formation can induce DNA damage in
keratinocytes.
In vitro studies in a wide range of cells have consistently demonstrated
that UVA-activated psoralen leads to mutations at 59TpA sites that are
Figure 2. Photoadduct structures. 49,59-monoadduct; 3,4-monoadduct;
interstrand crosslink.
Figure 3. Comparison of PUVA and UV mutations
in the p53 exons 5–8 from SCC. (A) T→A
transversions; (B) C→T, CC→TT transitions (for SCC
from mice treated with 8-MOP/UVA, psoriatic PUVA
patients, over sun-exposed humans, rental transplant
recipients, respectively). In (A) the prototypical T→A
transversions are evident in the SCC from mice exposed
solely to a PUVA regimen, but not in the human SCC
from the PUVA-treated psoriasis patients (unexpected)
nor in the other two groups of patients (expected). In
(B), except for the lack of CC→TT transitions, the
profile for the RTR is very similar to that for SCC
from over-sun-exposed humans. (C) The dinucleotide
sites for the mutation events in murine and human
SCC are compared. Part (C) further illustrates the
different effects of 8-MOP/UVA on murine and human
epidermal DNA.
known from in vitro studies to be psoralen photochemical hot spots
(Sage and Bredberg, 1991; Gunther et al, 1995). Whereas an in vivo
study of SCC from mice chronically exposed to PUVA also exhibited
this prototypical PUVA mutation spectrum in the p53 gene (Nataraj
et al, 1996), the first analyses of p53 mutations in human skin cancers
in PUVA-treated psoriasis patients yielded an unexpected mutation
spectrum (Nataraj et al, 1997; Wang et al, 1997). Very few of the
mutations were PUVA-type (T→A) at 59TpA sites (see Fig 3A).
Rather they were more characteristic of those resulting from solar
exposure (C→T, CC→TT, see Fig 3B). In the report by Wang et al
these clearly UVB-type events were most common. In the report by
Nataraj et al (1997) mutations were observed at 59TpG sites (nine out
of 24 prevalence versus one at a 59TpA site). It was argued that these
could be a variation of mutations usually seen at 59TpA sites seen in
the in vitro PUVA studies. Another possibility, however, is that these
sites are reflecting reactive oxygen species-mediated damage at G, C,
and/or T (Wang et al, 1998). Further complicating the interpretation
of mutation spectra is the observation that stable oxidation products
of cytosine and thymine can induce C→T transitions (Wang et al,
1998). Whether this oxidative damage (and the subsequent mutations)
is induced by the combination of 8-MOP and UVA or just UVA alone
remains to be determined.
In a recent review several possible explanations were proposed for
the unusual mutation spectrum in PUVA SCC (Gasparro et al, 1998).
Although photoadducts may form at 59TpA sites (note that this has
yet to be demonstrated in vivo, see below for additional comments),
these adducts may be processed with a high degree of accuracy,
resulting in the low frequency of mutations at these sites. This unusual
degree of fidelity might be traced to the so-called ‘‘A-rule’’ (Sagher
and Strauss, 1983). When the DNA replication machinery is paused
at a site of damage, there is a overwhelming tendency to insert an
adenine. Thus photoadducts at thymines may be tolerated better than
those at the other bases. It is also noteworthy that of all the p53
mutations characterized in human cancers (.7000), only 25% have
been detected at A:T base pairs (Greenblatt et al, 1994). Furthermore,
it is important to note that because early studies indicating a preponder-
ance of p53 mutations occured in exons 5–9, the examination of other
exons may prove to be a fruitful area for additional studies.
The possible cause for SCC in psoriasis patients treated with high
cumulative doses of PUVA may be explained by considering other
effects of PUVA on cells. A psoralen photoadduct specific monoclonal
antibody has been used to illustrate the presence of these photoadducts
in the suprabasal keratinocytes of PUVA-treated skin (Fig 4). It has
been assumed that SCC arise from these premutagenic photoadducts
formed during photochemotherapy; however, Krueger et al have shown
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that skin-infiltrating T cells in psoriasis patients are uniquely susceptible
to the effects of low to modest PUVA doses, whereas keratinocytes
appear to be unusually resistant (Johnson et al, 1996). The important
role of T cells as mediators of psoriasis and a target cell for therapeutic
intervention is also illustrated by the potency of cyclosporine and
DAB-IL2 regimens (Gottlieb et al, 1995). Taken together, the thera-
peutic effects of PUVA appear to be due to clearing of T cells and/or
alterations in cytokine production.
PUVA is also known to be immunosuppressive (Kripke, 1984).
Repeated PUVA therapy could attenuate immune surveillance in skin
and allow subpopulations of cells harboring preexisting p53 mutations
to develop into tumors (Jonason et al, 1996; Ren et al, 1997). These
tumors would be expected to express solar type mutations accumulated
during the lifetime of solar exposure humans’ experience. Such a series
of steps could account for the ‘‘early’’ development of SCC in the
PUVA cohort patients. These results also suggest that the epidemic of
skin cancer so widely publicised may be due more to the immune
suppressive effects of sunlight (as opposed solely to its direct genotoxic
effects). UV and PUVA cause similar mutations even though different
kinds of damage to cellular DNA are induced, the mechanism of SCC
development could be different as well.
Recent studies describing p53 mutations in the skin cancers of renal
transplant recipients (RTR) supports the possibility of immune effects
in the development of SCC (McGregor et al, 1997). The p53 mutation
spectrum obtained from the analysis of exons 5–9 of the p53 gene in
the skin cancers from these chronically immune suppressed patients is
remarkably similar to that for solar-induced skin cancer (Fig 3B).
There was a striking similarity in the frequency of mutations at
pyrimidines (primarily C), which was quite similar to that observed in
the sun-induced skin cancers. An alternate viewpoint has been presented
by Bennett et al (1997), who reported a lower incidence of p53
mutations in RTR SCC. In the latter study, SSCP analyses were not
performed and it is possible that some mutations were not detected.
Other clinical observations, however, are consistent with an immune-
effect hypothesis. Van de Kerkhof and de Rooij (1997) described the
occurence of multiple SCC in a psoriatic patient following 14 y of
PUVA (2500 exposures). At the time cyclosporine therapy was started
only three SCC had been detected. During 16 months of treatment
with cyclosporine 21 SCC appeared (one on the lower lip, three on
the arms, and 17 on the legs). In an animal study it had been previously
shown that cyclosporine was able to promote the growth of transplanted
UV-induced tumors (Servilla et al, 1987). Others described very similar
cases in which PUVA patients with SSC have been found to harbor
the human papillomavirus (Weinstock et al, 1995 and Ru¨bben et al,
1996). Both suggested that PUVA-induced immune suppression
increased the susceptibility to both HPV and SCC as a result of wild-
type p53 being inactivated by the HPV-produced E6 protein.
Figure 4. Section of human skin treated with 8-MOP and UVA and
then stained with 8G1. 8G1 is a monoclonal antibody recognizing 8-MOP
photoadducts in DNA (Santella et al, 1985). The binding of 8G1 to suprabasal
keratinocytes is reflected by the rhodamine-tagged goat-antimouse IgG.
Any other effective therapy for psoriasis will very likely need to
have similar effects on T cells. It is possible that repeated treatments
with other therapies (either systemic or topical) to clear psoriasis, could
also lead to an increased incidence of SCC (as in the case report on
cyclosporine described above). Although these alternate therapies may
not appear to act through direct genotoxic events (as in PUVA), they
may generate reactive oxygen species that can lead to the formation
of oxidative damage like 8-hydroxyguanine, with all of its concomitant
effects (Kvam and Tyrrell, 1997) or the release of clastogenic factors
(Filipe et al, 1997).
Understanding in vivo DNA photochemistry Although thymine
dimers are considered the most common DNA photoproduct,
mutations are rarely observed at T. There may be two contributing
factors. The first (the ‘‘A’’ rule) has already been discussed. The second
is that photoproduct prevalence based on laboratory studies does not
reflect the actual photochemistry that occurs in epidermal DNA.
Virtually all laboratory studies of DNA photochemistry have employed
UVC radiation (254 nm). Of course human skin is never exposed to
UVC because it does not penetrate the ozone layer (cut off near
~290 nm). When combined with the transmission properties of human
skin, it becomes clear that DNA in epidermal cells is exposed to a
range of wavelengths significantly different from those commonly
employed to study DNA photochemistry. In addition there may be
strong microenvironmental effects on DNA photochemistry that could
predispose base damage at specific DNA sequences (Ross and Yu,
1988). Using solar radiation, Tomassi et al (1997) showed that p53
mutation hot spots containing 5-methylcytosine (5 mC) within a
dipyrimidine sequence are 15-fold more susceptible to pyrimidine
dimer formation. These findings were confirmed by Drouin and
Therrien (1997) and Denisshenko et al (1997), who showed a correlation
between UVB-induced cyclobutane dimer formation and skin cancer
mutational hot spots in p53.
The absorption curve for 5 mC is red-shifted by 6 nm (compared
with cytosine, see Fig 5), which results in a 5–15-fold higher extinction
for 5 mC versus C between 300 and 315 nm (Pfeifer and Denisshenko,
1998). Thus, a selective absorption of photons by 5 mC could account
for the occurence of C→T and CC→TT mutations at dipyrimidine
sites containing 5 mC bases. This preference for photoproduct formation
at 5 mC sites may also explain the unusual action spectrum for the
induction of p53 recently reported by Deck et al (1998). A maximum
at 275 nm was reported and it was suggested that this might reflect a
non-DNA chromophore (peak not at 260 nm).
The relevance of the preceding discussion to PUVA resides in the
complex nature of 8-MOP photochemistry (see above). There may
be unique photochemical events at selected DNA sequences (a micro-
environmental effect). In addition, oxidative processes may produce a
Figure 5. UV absorption spectra for 5-methylcytosine and cytosine.
The spectrum for 5 mC is red shifted 6 nm. It should also be noted that the
spectrum for C itself is red-shifted compared with that for thymine (λmax ~
265 nm). The shaded region illustrates the additional absorptive properties of
5 mC at longer UVB wavelengths.
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mixture of clastogenic factors (Filipe et al, 1997; Przybyszewski et al,
1998) that could skew the in vivo mutation spectrum. While it may be
tempting to interpret the observed C→T mutations in PUVA SCC as
evidence of previous actinic damage (Gasparro et al, 1998), the
possibility that they arise by some other process cannot be discounted.
CONCLUSIONS
It is evident that molecular epidemiology has made significant contribu-
tions to our understanding of skin cancer caused by solar exposure
and/or PUVA. Clearly there is a need for more information. To
establish that a specific mutation is caused by a particular photochemical
reaction in cellular DNA, 8-MOP photoadduct mapping studies should
be performed to verify the location of photoadduct formation (or other
damage) under in vivo conditions.
For example, although it is known that 8-MOP photoadducts form
in cells treated with 8-MOP and UVA, their locations at specific
DNA sequences have not been determined. The extent of 8-MOP
photoadduct formation is reduced by three orders of magnitude for
in vivo treated cells (compared with in vitro treated DNA; Ross and
Yu, 1988). It is commonly assumed that the in vivo sites of photoadduct
formation will be the same as those found in vitro (Sage & Bredberg
1991). As illustrated above for pyrimidine dimer formation at 5 mC-
containing sites, however, in vitro and in vivo results may differ
significantly. The common tendency of AT rich transcription factor
binding sites to be occluded by nucleosomal assemblies may preclude
or at least reduce 8-MOP photoadduct formation at these sites (Klemm
et al, 1994). Furthermore, other sites where DNA damage is not
detected in vitro may become new hot spots as a result of nucleosome-
induced structures that provide new binding sites for 8-MOP at
sequences not considered hot spots in naked DNA.
For technical reasons it has been difficult to detect the formation
of base oxidation photoproducts (e.g. 8-hydroxyguanine); however,
evidence of its formation in epidermal DNA may be evident in the
observed p53 mutation spectrum from nonmelanoma skin cancers.
G→C and G→T transversions can be derived from 8hG (Palmer et al,
1997). It is also possible for some C→T transitions to arise from other
base oxidation photoproducts. Wang et al (1998) have shown that
stable oxidation products of cytosine and thymine can induce C→T
transitions. It is interesting to note that the distinctive action spectrum
for the photosensitized induction of 8hG extends far into the near UV
(long wavelength UVA). Although the endogenous sensitizing agent
(possibly NADH or porphyrins) remains to be determined, the
occurence of photoproducts by any means utilizing longer wavelengths
indicates the importance of studying these wavelengths for their
potential carcinogenic effects.1
The reviewed studies of p53 mutations shows that assumptions about
the causes of skin cancer need to be considered carefully. PUVA is a
well-tolerated efficacious therapy for psoriasis with well-characterized
and controllable side-effects. High dose patients at risk for SCC are
recognizable and any SCC that develop can be treated. It is appreciated
that this may not apply to PUVA melanomas. If the incidence of
melanoma in these patients continues to increase the dire concerns
about the continued use of PUVA would be justified. The current
PUVA management of psoriasis had been refined as the result of nearly
25 y of clinical experience. Before newer therapies are advocated to
replace PUVA, comparable efficacy and safety must be demonstrated.
The concern about the hazards of PUVA may be warranted but these
hazards may not be unique to PUVA.
The insights provided by the studies described here augur well for
the future of molecular epidemiology in augmenting our understanding
of skin cancer development, and possibly, prevention. For potential
1This observation also highlights the potential need for protection against
these wavelengths by sunscreens. An adequate UVB absorbing sunscreen could
easily prevent erythema while allowing the penetration of large amounts of
shorter visible radiation wavelengths and hence the accumulation of
premutagenic 8hG lesions or other oxidized bases (Tsurudrome et al, 1998).
Thus, it is important that studies evaluating sunscreen efficacy should employ
full spectrum solar radiation (actual or simulated) and not so-called sun lamps.
PUVA patients it may be possible to use a p53 mutation profile of
normal appearing skin (but containing actinic damaged-induced p53
mutations) as a pre-PUVA screen for psoriasis patients likely to develop
skin cancers. Other studies might also include the analysis of p53
mutations in malignant melanomas detected in PUVA patients (Stern
et al, 1997). It will be important to know whether these mutations
have distinctive features of PUVA-induced DNA damage or whether
they are more like the less common p53 mutations typically found in
melanomas (Albino et al, 1994; Weiss et al, 1995).2 In this regard it
will be important to consider all types of UV-induced mutations –
both the prototypical C→T and the CC→TT transitions as well as
mutations arising from the newly appreciated significance of oxidized
DNA bases. In evaluating the results of these kinds of studies, it should
be kept in mind that carcinogenesis is a complex process and that there
are redundant molecular controls of proliferation, mutations in p53
could be a central event, perhaps even a driving force, in one
malignancy and not another.
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